Form D · Biotechnology

Thiogenesis Therapeutics, Corp.

Toronto, A6 · CIK 0001877778

Offering snapshot reported Jun 9, 2026 · SEC filing

Reported sold
$29K
Offering amount: $29K
Investors reported
0
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 1, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 9, 2026Initial$28,964No comparison0SEC filing
Aug 8, 2025Initial$125,450No comparison0SEC filing
Dec 20, 2023Initial$252,281No comparison1SEC filing
Nov 25, 2022Initial$218,303No comparison3SEC filing
Aug 11, 2021Initial$252,756No comparisonNot reportedSEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-586737
U.S. dollar amount is based on the Bank of Canada exchange rate of 0.7227 reported on June 1, 2026.

Source: Form D, filed Jun 9, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Neil A. Johnson Director, Executive
Hogan W. Mullally Director
W. Hogan Mullally Director
Brook G. Riggins Director, Executive
Patrice Rioux Director, Executive
Christopher Starr Director
Kim Tsuchimoto Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
4 King Street West, Suite 401
Toronto, A6, M5H 1B6